Clinical Practice Points
-
What is Already Known About This Subject?Hepatic arterial infusion (HAI) pumps represent 1 promising treatment strategy for patients presenting with liver only or predominant tumors. HAI therapy is a form of locoregional therapy which administers chemotherapy directly into the hepatic artery, thus limits systemic exposure and spares other organs from toxicity. According to the National Comprehensive Cancer Network Guidelines (NCCN), placement of a HAI pump, in combination with systemic chemotherapy, has a category 2B recommendation for centers with the requisite expertise to perform this procedure. However, the utility of HAI pumps for patients with previously treated relapsed/refractory colorectal cancer (CRC) with colorectal liver metastases (CRLM) remains unclear.
-
What are the New Findings?Here, we describe a case of heavily pretreated patient with CRC and CRLM unusually responsive to HAI chemotherapy. Our patient had a progression free survival (PFS) of 20.2 months with HAI therapy, versus a PFS of 3 to 6 months with systemic chemotherapy therapy. Furthermore, in this case, the patient has been able to stay off systemic therapy for over a year by the time of this publication. Based on the patient's response, HAI therapy may slow the rate of disease progression compared to other therapies, as it might “reset the clock” as it did for this patient's very aggressive biology.
-
How Might it Impact on Clinical Practice in the Foreseeable Future?We believe this to be the first published case report of a patient with previously treated HER2+ CRC who had progressed on anti-HER2 therapy, who had a substantial response from treatment with FUDR HAI chemotherapy. Our report adds to the dearth of the literature in this patient population, and supports use of HAI chemotherapy as a potential treatment strategy for patients with relapsed, refractory CRLM. This case suggests that HAI chemotherapy with FUDR in combination with systemic therapy has the potential to provide long-term responses even for patients with CRLM refractory to multiple lines of chemotherapy.
Keywords
Abbreviations:
CapeOx (Oral capecitabine and intravenous oxaliplatin), CT (computed tomographic), FOLFIRI (folinic acid, fluorouracil, irinotecan), HAI (hepatic arterial infusion), FUDR (floxuridine), LFT (liver function test), CRC (colorectal cancer), CRLM (colorectal liver metastases), NCCN (National Comprehensive Cancer Network Guidelines), MSS (microsatellite stable), CPS (combined positive score), MRI (magnetic resonance imaging)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer statistics, 2022.CA Cancer J Clin. 2022; 72: 7-33
- Population-based audit of colorectal cancer management in two UK health regions.J Br Surg. 1997; 84: 1731-1736
- Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.J Clin Oncol. 2008; 26: 5721
- Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis. International Scholarly Research Notices.ISRN Oncol. 2011; 2011763245
- Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5-and 10-year survivors.J Surg Oncol. 2011; 103: 796-800
- Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors.Clin Epidemiol. 2012; 4: 283-301https://doi.org/10.2147/clep.S34285
- Hepatic arterial infusional chemotherapy in the management of colorectal cancer liver metastases.Hepat Oncol. 2015; 2: 275-290https://doi.org/10.2217/hep.15.9
- Multisciplinary management of patients with liver metastasis from colorectal cancer.World J Gastroenterol. 2016; 22: 7215-7225https://doi.org/10.3748/wjg.v22.i32.7215
- Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases: a review.JAMA Surg. 2019; 154: 768-776https://doi.org/10.1001/jamasurg.2019.1694
- The state of hepatic artery infusion chemotherapy in the management of metastatic colorectal cancer to the liver.Chin Clin Oncol. 2019; 8: 54https://doi.org/10.21037/cco.2019.09.01
- Review of intra-arterial therapies for colorectal cancer liver metastasis.Cancers (Basel). 2021; 13: 1-27https://doi.org/10.3390/cancers13061371
- Getting chemotherapy directly to the liver: the historical evolution of hepatic artery chemotherapy.J Am Coll Surg. 2021; 232: 332-338https://doi.org/10.1016/j.jamcollsurg.2020.11.013
- Locoregional liver-directed therapies to treat unresectable colorectal liver metastases: a review.Oncology (Williston Park). 2022; 36: 108-114https://doi.org/10.46883/2022.25920945
- Hepatic artery infusion pumps.J Surg Oncol. 2020; 122: 70-77https://doi.org/10.1002/jso.25913
- The role of floxuridine in metastatic liver disease.Mol Cancer Ther. May 2009; 8: 1015-1025https://doi.org/10.1158/1535-7163.Mct-08-0709
Cancer NCCNC. (Version 1.2022). Available at:https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed October 28, 2022.
- HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression.PLoS One. 2014; 9: e98528https://doi.org/10.1371/journal.pone.0098528
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.Lancet Oncol. 2016; 17: 738-746https://doi.org/10.1016/s1470-2045(16)00150-9
- Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.J Clin Oncol. 2009; 27: 3465-3471https://doi.org/10.1200/jco.2008.20.1301
- Regional therapy for colorectal cancer liver metastases: which modality and when?.J Clin Oncol. 2022; 40: 2806-2817https://doi.org/10.1200/jco.21.02505
- Actual 10-year survival after resection of colorectal liver metastases defines cure.J Clin Oncol. 2007; 25: 4575-4580https://doi.org/10.1200/jco.2007.11.0833
- Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.Ann Surg. 2015; 261: 353-360https://doi.org/10.1097/sla.0000000000000614
- Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution.Ann Surg Oncol. 2013; 20: 2901-2907https://doi.org/10.1245/s10434-013-3009-3
- Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.J Surg Oncol. 2018; 117: 634-643https://doi.org/10.1002/jso.24898
- Hepatic metastasis from colorectal cancer.Euroasian J Hepatogastroenterol. 2017; 7: 166-175https://doi.org/10.5005/jp-journals-10018-1241
- Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?.J Clin Oncol. 2009; 27: 1829-1835https://doi.org/10.1200/jco.2008.19.9273
- Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.N Engl J Med. 1999; 341: 2039-2048https://doi.org/10.1056/nejm199912303412702
- Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis.J Clin Oncol. 2017; 35: 1938-1944https://doi.org/10.1200/jco.2016.71.8346
- Salvage regional therapy using hepatic artery infusion pump in unresectable chemotherapy resistant colorectal liver metastases.Am J Surg. 2022; 223: 1151-1156https://doi.org/10.1016/j.amjsurg.2021.10.032
Administration USFD. FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer. Accessed Feb 12, 2023.
- Hepatic arterial infusion in the management of colorectal cancer liver metastasis: Current and future perspectives.Dig Liver Dis. 2018; 50: 220-225https://doi.org/10.1016/j.dld.2017.12.004
- Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement.Curr Oncol. 2014; 21: e129-e136https://doi.org/10.3747/co.21.1577
- Precision medicine for the treatment of colorectal cancer: the evolution and status of molecular profiling and biomarkers.Curr Colorect Cancer Rep. 2021; 17: 55-68
- Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.Ann Surg Oncol. 2008; 15: 219-226https://doi.org/10.1245/s10434-007-9581-7
- Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies.J Surg Oncol. 2016; 114: 655-663https://doi.org/10.1002/jso.24399
Article info
Publication history
Published online: February 23, 2023
Accepted:
February 21,
2023
Received in revised form:
February 14,
2023
Received:
December 20,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
